Nader Rifai,"2" Masiyuki Sakamoto,' Terence Law,"5 Orah Platt,"3 Mohamad Mikati,4 Carrie C. Armsby,' and Carlo Brugnara" Clotrimazole (CLI) has recently been shown to be a potent and specific inhibitor of the Ca2-activated K channel and to thereby prevent K loss and cellular dehydration of sickled erythrocytes. This evidence suggests that oral CLI may be a useful new therapy for sickle cell disease. Here, we describe the development of an HPLC assay to measure CLT, a method we used to study the pharmacokinetics and transport of CLT in normal volunteers. The assay's linear range extended to 10 moVL; the detection limit was 0.1 moVL, analytical recovery 97.7%, and run-to-run imprecision (CV) <4.7%. In unaffected subjects, CLT concentration peaked within 6 h of oral administration and returned to close to baseline by 24 h. High-density lipoproteins appear to be the main carriers of this drug in both normo-and hypertriglyceridemic plasma. We conclude that the method described here is ideally suited for therapeutic monitoring of CLI concentrations.
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Clotrimazole (CLT) is a highly effective drug against a broad spectrum of fungi (1, 2 )7 In addition to its antimycotic activity, CLT has been shown in vitro to specifically and potently inhibit the Ca2-activated K channel, known as the Gardos channel, in sickle erythrocytes (3, 4) . Four assays have already been described.
Two HPLC methods determine CLT in pharmaceutical formulations (5, 6) . One bioassay and one two-dimensional paper chromatographic method measure CLT in various body fluids (7, 8) . Here, we describe the development of a reversed-phase HPLC assay for determining CLT concentration in whole blood and plasma. We used the assay to study the pharmacokinetics and distribution of CLT in the blood. 
Materials and Methods

Reagents
Results and Discussion
A typical chromatogram from the plasma or wholeblood extract of a subject taking CLT is presented in Fig.  1 An extracted urine specimen shows the same chromatograin as in Fig.  1 but without the CLT peak (chromatogram not shown), in agreement with a previous report (8) . We are currently testing the abffity of these metabolites to inhibit the Gardos channel.
The calibration curves in both whole blood and plasma, with CLT concentrations ranging from 0 to 5 Mmol/L, were linear (for whole blood, slope = 0.82 and r = 0.99; for plasma, slope = 1.28 and r = 0.99) and reproducible:
For whole blood, the average CV for the calibrators was 7.1% (n = 18); for plasma, the average CV for the calibrators was 4.9% (n = 21). Because of the significantly different slopes (P <0.0025) of the calibration curves of CLT in whole blood and plasma, the type of calibrators should be the same as the type of specimens for accurate determination of CLT concentration. The day-to-day precision, reflected by CV, was determined with 10 replicates of plasma-based qualitycontrol materials at two drug concentrations, with assay of a newly extracted set of calibrators each day. For drug concentrations of 1 and 5 Mmol/L, the precision was 4.7% and 2.6%, respectively.
A recovery study was performed by adding to drug-free plasma and whole blood from four subjects known amounts of the purifieddrug. At CLT concentrations of 0.5, 1, and 2
MmoIIL, the mean (SD) analytical recoveries in plasma were 99.6% (6.7%), 97.2% (7.9%), and 96.3% (7.6%), and in whole blood were 90.4% (8.8%), 94.2% (7.0%), and 100% (4.8%), respectively. Furthermore, the assay could detect as little CLT as 0. whole blood than in serum, and that plasma CLT is about twice that of serum (7) . Our data indicate that whole blood and plasma CLT concentrations change proportionally, up to 10 h, after a single drug dose. In contrast to the earlier findings, only about 37% (SD 8.4%) of whole-blood CLT is present in the cellular compartment, the remaining portion being in the plasma (determined at four time points in three subjects).
In addition, we noted no significant difference between serum and plasma CLT concentrations (plasma 0.55 ± 0.47 Mmol/L, serum 0.67 ± 0.58 Mmol/L, n = 4, P <0.5). The exact cause of the discrepancy between the findings of our study and that of Seo et al. is unknown, but is probably related to the fact that the latter is a bioassay.
In the present study, we examined the distribution of CLT in plasma by determining its concentration in the albuminand lipoprotein-bound fractions.
Free CLT (or unbound CLT) concentration was also assessed. Our data indicate that free CLT is present in plasma in very minute amounts.
In fact, its concentration was <0.1
MmoI/L, the detection limit of this assay. This finding is consistent with a previous report indicating that <1% of CLT is present in its active form (8) . In addition, only -4% (SD 3.5%) of this drug was shown to be bound to albumin when determined in four subjects 4 h after dose.
Lipoproteins play a major role in the in vivo transport of many lipophilic drugs, and in part explain some of the variability observed in pharmacokinetic and pharmacodynamic profiles. 
